Surgical ApproachPhase 4NCT05147207

SuperPath Versus Posterior Approach for THA

A Phase 4 study testing Superpath Approach in people with Surgical Approach and Hip Arthropathy, run by Dr. Gavin Wood at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 21 to 100 years
Conditions the study is for: Surgical Approach, Hip Arthropathy
What is being tested?: Superpath Approach
Type of treatment: Surgery or procedure
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 45 participants
Where: 1 siteCanada
Study dates: 1 Apr 2017to 1 Jun 2021
Phase: Phase 4
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 21 to 100 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis;
Inflammatory degenerative joint disease including rheumatoid arthritis;
Correction of functional deformity.
Subject is skeletally mature (21 years of age or older);
Subject is a candidate to be implanted with the specified combination of components;
Subject is willing and able to complete required study visits and assessments;

Show all 9Show fewer

Subject plans to be available through the follow-up visits;
Subject is willing to sign the approved informed consent document.
Subjects with a previous THA in the contralateral hip are eligible for enrollment provided it has been at least 1 year since the contralateral THA and the contralateral THA is asymptomatic and not pending revision. Simultaneous bilateral THA subjects will not be permitted to enroll.

Who cannot join

Subject has overt infection or distant foci of infections;
Subject has rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram;
Subject with inadequate neuromuscular status (e.g. prior paralysis, fusion and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable;
Subject has a neuropathic joints;
Subject has hepatitis or HIV infection;
Subject has a neurological or musculoskeletal disease that may adversely affect gait or weight-bearing;

Show all 10Show fewer

Subject is currently enrolled in another clinical investigation that could affect the endpoints of this study;
Subject is unwilling or unable to sign the informed consent document;
Subject has documented substance abuse issues;
Subject has a body mass index (BMI) of greater than 40;

Trial locations and contacts

1 site in 1 country.

Canada1 site

Kingston General Hospital
Kingston, Ontario, K7L 2V7

Other trials in Canada

About this study

Official title: Supercapsular Percutaneously-Assisted Total Hip (SuperPATH®) Versus Conventional Posterior Approach for Total Hip Arthroplasty: A Prospective Randomized Controlled Study

The SuperPATH approach is a minimally invasive approach for total hip arthroplasty. This project randomized patients to the SuperPath versus posterior approach. Outcomes examined included functional, VAS pain, narcotic utilization, perioperative outcomes, and radiographic component positions. Participants were followed for 2 years. The aim was to examine if the SuperPATH approach provided significant advantages over the posterior approach on functional testing or return to work for patients.

Read the detailed description

Background: The Supercapsular Percutaneously-Assisted Total Hip (SuperPATH) approach is a minimally invasive approach for total hip arthroplasty. It has been reported to show earlier mobilization, better gait kinematics, and short hospital length of stay. Our primary objective was to compare functional tests of timed up and go and timed stair climb preoperatively, at discharge, 2 weeks, and 6 weeks postoperatively. Secondary objectives included the return to function in weeks, Oxford hip scores, visual analog scale, narcotic utilization, perioperative outcomes, and radiographic component positions.

Methods: Forty-six patients were randomized into two groups on the surgery day: the SuperPATH group (25 patients) and the Posterior group (20 patients). Outcomes examined included functional, VAS pain, narcotic utilization, perioperative outcomes, and radiographic component positions.

Conditions: Surgical Approach, Hip Arthropathy
Being tested: Superpath Approach

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Superpath ApproachProcedure or surgery
This is a minimally invasive surgical approach for THA.

Study groups in NCT05147207
Study group	Role	What they receive
Superpath	Experimental	This is a minimally invasive surgical approach. Receives: Procedure: Superpath Approach
Posterior Approach	No intervention	This is the traditional THA surgical approach used.

What is being measured

The primary outcome is the main question the study is designed to answer.

Functional Outcomes TUG
Timed up and go test
Measured: 6 weeks
Functional Outcomes TSC
Timed stair climb
Measured: 6 weeks

Secondary outcomes (2)

Subjective Measure
Oxford Hip Score - score from 0 (severe hip arthritis) to 48 (satisfactory joint function)
Measured: 3 months
Pain Score
Visual Analog Scale - score from 0 (no pain) to 10 (worst pain)
Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Apr 20171 Jun 2021

First posted7 Dec 2021
Study start1 Apr 2017
Primary completion1 May 2019
Study completion1 Jun 2021

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (1)Papers the sponsor has linked to this study.
Other trials for Surgical ApproachStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 4
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: superpath approach versus posterior approach
Masking: None (open label)
Enrolment: 45 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05147207
Sponsor's protocol ID: SURG-387-17
Status last verified: Aug 2026
First submitted: 20 Oct 2021
Last updated: 12 Aug 2026
Results posted: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Publications

Khoja YT, Habis AA, Wood GCA. The Supercapsular Percutaneously Assisted Total Hip Approach Does Not Provide Any Clinical Advantage Over the Conventional Posterior Approach for THA in a Randomized Clinical Trial. Clin Orthop Relat Res. 2023 Jun 1;481(6):1116-1125. doi: 10.1097/CORR.0000000000002449. Epub 2022 Nov 8.
PubMed 36350098

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruitingObservational study
Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers
MASLD, T2DM (Type 2 Diabetes Mellitus)
Not yet recruiting
Ureteral Access Strategies in Retrograde Intrarenal Surgery
Nephrolithiasis, Kidney Calculi
RecruitingPhase 3
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
Locally Advanced Rectal Carcinoma
Not yet recruiting
The Contribution of Accelerated Recovery (mERAS) Approach to Postoperative Recovery in Pediatric Laparoscopic Surgery Cases
mERAS Intervention, The ASA (American Society of Anesthesiologists) Score
Recruiting
Impact of a Multidisciplinary Approach in the Perioperative Geriatrics Unit on Functional Status of Patients Aged 70 and Over Operated on for Colorectal Cancer
Colorectal Cancer, Surgery

All Surgical Approach trials

Study at a glance

From the registry record, last updated by the sponsor on 12 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Supercapsular Percutaneously-Assisted Total Hip (SuperPATH®) Versus Conventional Posterior Approach for Total Hip Arthroplasty: A Prospective Randomized Controlled Study
ClinicalTrials.gov ID: NCT05147207
Acronym / sponsor ID: SURG-387-17
Conditions: Surgical Approach, Hip Arthropathy
Phase: Phase 4
Study type: Interventional
Recruitment status: Completed
Enrolment: 45 participants (actual)
Lead sponsor: Dr. Gavin WoodUniversity, hospital or other
Study start: 1 Apr 2017 (actual)
Primary completion: 1 May 2019 (actual)
Study completion: 1 Jun 2021 (actual)
First posted: 7 Dec 2021 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2
Model description: superpath approach versus posterior approach

Arm	Type	Receives
Superpath	Experimental	Procedure: Superpath ApproachThis is a minimally invasive surgical approach.
Posterior Approach	No intervention	–This is the traditional THA surgical approach used.

Who may qualify

Ages: 21 to 100 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (9 listed)

Non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis;
Inflammatory degenerative joint disease including rheumatoid arthritis;
Correction of functional deformity.
Subject is skeletally mature (21 years of age or older);
Subject is a candidate to be implanted with the specified combination of components;

Key exclusion criteria (10 listed)

Subject has overt infection or distant foci of infections;
Subject has rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram;
Subject with inadequate neuromuscular status (e.g. prior paralysis, fusion and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable;
Subject has a neuropathic joints;
Subject has hepatitis or HIV infection;

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Superpath ApproachThis is a minimally invasive surgical approach for THA.	Procedure or surgery	Superpath

Primary outcome

Functional Outcomes TUG
Time frame: 6 weeks
Timed up and go test
Functional Outcomes TSC
Time frame: 6 weeks
Timed stair climb

2 secondary outcomes

Subjective Measure
Time frame: 3 months
Pain Score
Time frame: 1 month

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 12 Aug 2026.
Derived from this study: PubMed 36350098Khoja YT, Habis AA, Wood GCA. The Supercapsular Percutaneously Assisted Total Hip Approach Does Not Provide Any Clinical Advantage Over the Conventional Posterior Approach for THA in a Randomized Clinical Trial. Clin Orthop Relat Res. 2023 Jun 1;481(6):1116-1125. doi: 10.1097/CORR.0000000000002449. Epub 2022 Nov 8.
Individual participant dataSharing planned: No

Related trials for Surgical Approach

Active, not recruitingObservational study
Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers
MASLD, T2DM (Type 2 Diabetes Mellitus)
Not yet recruiting
Ureteral Access Strategies in Retrograde Intrarenal Surgery
Nephrolithiasis, Kidney Calculi
RecruitingPhase 3
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
Locally Advanced Rectal Carcinoma
Not yet recruiting
The Contribution of Accelerated Recovery (mERAS) Approach to Postoperative Recovery in Pediatric Laparoscopic Surgery Cases
mERAS Intervention, The ASA (American Society of Anesthesiologists) Score
Recruiting
Impact of a Multidisciplinary Approach in the Perioperative Geriatrics Unit on Functional Status of Patients Aged 70 and Over Operated on for Colorectal Cancer
Colorectal Cancer, Surgery

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Superpath Approach in people with Surgical Approach and Hip Arthropathy, run by Dr. Gavin Wood at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Functional Outcomes TUG (time frame: 6 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05147207, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.